3489 Canterbury Place
68 articles with biOasis
BIOASIS TECHNOLOGIES INC. announced that it has granted stock options to acquire a total of 1,495,000 common shares effective June 30, 2020 at a price of $0.31 per share to directors and officers of the company.
BIOASIS TECHNOLOGIES INC. (“Bioasis”) (TSXV:BTI.V; OTCQB:BIOAF),a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including rare genetic diseases, brain cancers, neurodegenerative diseases and pain,
Bioasis Technologies Announces the Appointment of Dr. May Orfali to the Position of Consultant Chief Medical Officer
Bioasis Technologies Inc. announced today the appointment of Dr. May Orfali to the position of Consultant Chief Medical Officer, effective immediately.
GUILFORD, CONN ., Feb. 19, 2020 /PRNewswire/ -- Bioasis Technologies Inc. (OTCQB:BIOAF; TSX.V:BTI), (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medica
Bioasis to Present at the 22nd Annual BIO CEO Investor Conference and the OTC Markets 2020 Virtual Investor Conference
Bioasis Technologies Inc. announced that Dr. Deborah Rathjen, Executive Chair and Chief Executive Officer of Bioasis will present at the following conferences
This News Release Is Intended for Distribution in Canada Only and Is Not Intended for Distribution to United States Newswire Services or Dissemination in the United States
BIOASIS TECHNOLOGIES INC. is pleased to announce that all resolutions were passed by the requisite majority at its annual general meeting held earlier today in Toronto, Ontario.
Dr. John DeGroot, Dr. Hope Rugo and Dr. Javier Cortés Join Medical Oncology Advisory Board
Bioasis Announces Issuance of Japanese Patent Relating to xB3™ Platform Technology for The Delivery of Therapeutic Agents Across The Blood-Brain Barrier
The patent relates to Bioasis’ P97 conjugates with therapeutic agents where the P97 has the ability to transport the agent across the BBB.
CORRECTING and REPLACING Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2019
Bioasis Technologies Inc. announced it has filed its unaudited financial statements and management’s discussion and analysis for the period ended August 31, 2019
Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending August 31, 2019
Bioasis Technologies Inc. announced it has filed its audited annual financial statements and management’s discussion and analysis for the period ended August 31, 2019.
Bioasis Technologies Inc. announced that it has granted stock options to acquire a total of 1,576,240 common shares at a price of $0.27 per share to directors and officers of the company, including 510,000 options granted to Mario Saltarelli, who joined the board as a new director in May 2019 and 391,240 options granted to Deborah Rathjen, President & Chief Executive Officer, in lieu of cash compensation.
Bioasis Announces Allowances of Patent Applications in the U.S. and Europe Relating to xB3 Platform Technology and Key Therapeutic Indications
U.S. Patent Office and European Patent Office issue allowances of patent applications relating to iduronate-2-sulfatase (“IDS”) polypeptide/xB3 conjugates
BIOASIS TECHNOLOGIES INC. announced that it has applied for approval from the TSX Venture Exchange to extend the expiry date of 5,797,795 common share purchase warrants issued to subscribers pursuant to the private placement of units which closed on April 11, 2017.
BIOASIS TECHNOLOGIES INC. today announced that its board of directors has appointed Dr. Deborah A. Rathjen as president and chief executive officer.
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2018
BIOASIS TECHNOLOGIES INC. announced that it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended Nov. 30, 2018.
1/18/2019Pharma and biotech companies make changes to their board and leadership teams to advance pipelines and strategies, at SQZ, AstraZeneca, Bioasis, and more.
1/11/2019Biopharma companies strengthen the leadership teams during the annual J.P. Morgan Healthcare Conference.
Bioasis Announces Agreement With Leading Pharmaceutical Company for Pre-Clinical Research Using the xB3 Platform Technology
Under the terms of the Material Transfer Agreement, Bioasis will receive $500,000
12/17/2018With the year closing out, biotech and pharma companies are making adjustments to their leadership ranks and boards of directors.